MedCrave
Step into the World of Research

Journal of Human Virology & Retrovirology

Research Article

Open Access

CrossMark

The protective role of sickle cell trait against plasmodium falciparum malaria

Abstract

Malaria caused by Plasmodium falciparum remains a major global health burden, disproportionately affecting populations in sub-Saharan Africa. Over millennia, the intense selective pressure exerted by malaria has driven the emergence of human genetic adaptations that confer partial resistance to infection. Among these, the sickle cell trait (heterozygous HbAS) represents one of the most compelling examples of natural protection against P. falciparum malaria. This review explores current knowledge on the molecular, physiological, immunological, and evolutionary mechanisms underlying this protection. At the genetic level, the β-globin gene mutation leading to hemoglobin S alters erythrocyte physiology, impairing parasite growth and promoting early clearance of infected cells. Epidemiological studies consistently demonstrate that HbAS individuals experience lower malaria incidence, reduced parasitemia, and diminished risk of severe clinical manifestations such as cerebral malaria and severe anemia. Mechanistically, factors such as intermittent sickling under hypoxic conditions, increased oxidative stress, and altered cytoadherence impede parasite maturation and sequestration. Moreover, HbAS erythrocytes modulate innate and adaptive immune responses, enhancing macrophage activity and cytokine balance, thereby limiting parasite proliferation and immunopathology. From an evolutionary perspective, this heterozygote advantage exemplifies balanced polymorphism, wherein malaria resistance maintains the deleterious HbS allele in endemic populations. Understanding these multifactorial protective pathways not only illuminates gene–environment co-evolution but also provides a foundation for novel therapeutic strategies, including host-directed antimalarial interventions and precision medicine in endemic regions. This review integrates genetic, biochemical, immunological, and epidemiological insights to underscore the enduring biomedical significance of the sickle cell–malaria relationship.

Keywords: plasmodium falciparum, sickle cell trait, hemoglobin S, malaria resistance, balanced polymorphism and immunohematology.

Volume 12 Issue 1 - 2025

Moses Adondua Abah,[1,2] Ezekiel Uduak Archibong,[3] Micheal Abimbola Oladosu,[2,4] Ezeudu Paschal Chikelum,[5] Adaora Chiamaka Ekekwe,[6] Silas Verwiyeh Tatah,[1] Ayoade Babatunde Olanrewaju,[7] Ochuele Dominic Agida[1,2]

[1]Department of Biochemistry, Faculty of Biosciences, Federal University Wukari, Nigeria
[2]ResearchHub Nexus Institute, Nigeria
[3]Accident and Emergency department, University of Uyo Teaching Hospital, Nigeria
[4]Department of Biochemistry, Faculty of Basic Medical Sciences, University of Lagos, Nigeria
[5]Department of Medicine and Surgery, Faculty of Clinical sciences, University of Lagos, Nigeria
[6]Department of Community Health and Primary Care, University of Lagos, Nigeria
[7]Department of Biology and Environmental Science, College of Arts and Sciences, University of New Haven, USA

Correspondence: Moses Adondua Abah, Department of Biochemistry, Faculty of Biosciences, Federal University Wukari, Taraba State, Nigeria, Tel +234 907 823 8896

Received: November 28, 2025 | **Published:** December 08, 2025

Introduction

Malaria, caused predominantly by *Plasmodium falciparum*, remains one of the most formidable infectious diseases globally, posing a persistent threat to public health and human survival, as illustrated by global malaria death rates (Figure 1). Despite major advances in control strategies, the World Health Organization[2] reported approximately 249 million malaria cases and 608,000 deaths in 2022, with sub-Saharan Africa accounting for the vast majority of this burden. Children under five years and pregnant women remain the most vulnerable groups. The disease, transmitted through the bites of infected female Anopheles mosquitoes, is highly complex: of the five *Plasmodium* species infecting humans, *P. falciparum*, *P. vivax, P. ovale, P. malariae*, and *P. knowlesi*, *P. falciparum* is the most virulent, responsible for most severe manifestations and fatalities.[3] Its pathogenesis involves intricate host–parasite interactions, including erythrocyte invasion, immune dysregulation, and endothelial dysfunction, which culminate in complications such as cerebral malaria, metabolic acidosis, and severe anemia.[4]

Following mosquito inoculation, *P. falciparum* sporozoites migrate to the liver, undergo schizogony, and release merozoites that invade red blood cells. Infected erythrocytes undergo biochemical remodeling characterized by the expression of *P. falciparum* erythrocyte membrane protein 1 (PfEMP1), facilitating cytoadherence to endothelial cells. This sequestration leads to microvascular obstruction, tissue hypoxia, and inflammation.[5] Despite extensive efforts in vector control and chemotherapeutic interventions, malaria persists, highlighting the critical influence of host genetic factors in modulating disease susceptibility and outcomes. The prolonged evolutionary confrontation between humans and *P. falciparum* has driven the selection of genetic polymorphisms that confer partial protection against severe malaria. Among the most prominent of these adaptations are glucose-6-phosphate dehydrogenase (G6PD) deficiency, α-thalassemia, Duffy antigen negativity, and notably, the sickle cell trait (SCT).[6,7]



Figure 1 Global Malaria death rates. The map demonstrates the global distribution of malaria mortality, emphasizing endemic regions where *Plasmodium falciparum* contributes most significantly to disease burden.[1]

The sickle cell trait arises from a single nucleotide substitution in the β-globin gene on chromosome 11, replacing glutamic acid with valine at position six (Glu6Val). This mutation produces sickle hemoglobin (HbS), which, when inherited heterozygously (HbAS), confers a survival advantage in malaria-endemic regions without the

pathological consequences seen in homozygous individuals (HbSS) who develop sickle cell disease (SCD). Globally, more than 300 million individuals carry the HbS allele, with prevalence exceeding 20% in parts of West Africa (Luzzatto, 2012). This distribution mirrors that of malaria, exemplifying a classic case of balanced polymorphism where the heterozygous advantage offsets the deleterious effects of homozygosity. The link between SCT and malaria resistance was first recognized by Anthony Allison in the 1950s, who demonstrated that children with the HbAS genotype were less likely to develop severe malaria than those with normal hemoglobin (HbAA). Individuals with HbAS benefit from a remarkable survival advantage in malaria-endemic areas due to their partial resistance to *P. falciparum* infection.[8] This discovery established one of the most compelling examples of natural selection driven by infectious disease.

Several biological mechanisms underpin the protective effect of the sickle cell trait against P. falciparum. At the cellular level, erythrocytes containing HbAS are less conducive to parasite invasion and growth. Under low oxygen tension, these cells undergo reversible sickling, which disrupts parasite metabolism, promotes oxidative stress, and enhances clearance of infected cells by the spleen and macrophages. Alterations in ion balance and membrane integrity hinder cytoadherence, thereby reducing microvascular sequestration. Immunologically, HbAS individuals appear to mount more efficient innate and adaptive responses, enabling early parasite control and reduced inflammatory damage.[9] Epidemiological studies across Africa, including large cohorts in Kenya, have shown that HbAS individuals exhibit 60–90% reduced risk of severe malaria syndromes such as cerebral malaria and severe anemia, even though infection rates remain similar.[10,11] Despite this substantial protection, SCT does not confer complete immunity, and carriers may still experience mild to moderate malaria episodes. Furthermore, the inheritance of the HbS allele presents genetic challenges when two carriers reproduce, as offspring face a 25% risk of inheriting homozygous sickle cell disease. This genetic trade-off underscores the importance of integrating genetic counseling and public health education into malaria-endemic regions such as Nigeria, which bears one of the world's highest dual burdens of malaria and SCD.

This review aims to provide a comprehensive synthesis of current evidence on the protective role of the sickle cell trait against *Plasmodium falciparum* malaria. It critically examines the molecular, cellular, and immunological mechanisms underlying HbAS-mediated protection and explores epidemiological patterns across endemic populations. Additionally, it highlights the evolutionary significance of the HbS allele as a model of gene–environment coadaptation and discusses its clinical implications for disease management and genetic counseling in high-burden regions. By integrating insights from molecular biology, population genetics, and public health, this review seeks to enhance understanding of how SCT shapes malaria susceptibility and to inform future research and control strategies targeting host–pathogen interactions.

Genetic and molecular basis of the sickle cell trait

The genetic and molecular foundation of the sickle cell trait (HbAS) represents a cornerstone in understanding host resistance to *Plasmodium falciparum* malaria. The β-globin gene mutation responsible for sickle hemoglobin (HbS) exemplifies how a single nucleotide polymorphism (SNP) can yield profound biological consequences through structural, biochemical, and evolutionary mechanisms. The HbAS genotype provides a striking instance of balanced polymorphism, an evolutionary compromise between deleterious homozygosity and beneficial heterozygosity in malaria-endemic environments.[7,12] This section examines the structure and genetics of hemoglobin variants, the inheritance and distribution of the HbS allele, and the selective pressures that have maintained its frequency in human populations.

Structure and genetics of normal hemoglobin (HbA) and sickle hemoglobin (HbS)

Normal adult hemoglobin (HbA) consists of two α- and two β-globin chains ($\alpha_2\beta_2$), each containing a heme group capable of reversible oxygen binding. The β-globin gene (HBB), located on chromosome 11p15.5, encodes the β chain of hemoglobin and is highly conserved across vertebrates.[13] The sickle mutation results from a single transversion (A→T) in the sixth codon of HBB, substituting valine for glutamic acid (Glu6Val) on the β-globin chain. This seemingly minor alteration dramatically changes hemoglobin's physicochemical properties, promoting polymerization under deoxygenated conditions.[14] Polymerized deoxy-HbS distorts erythrocyte morphology into a sickled shape, altering cell deformability, ion transport, and redox homeostasis.

As illustrated in **Figure 2**, the upper panel shows the quaternary structure of normal hemoglobin (HbAA), in which globin chains maintain their soluble, flexible conformation under both oxygenated and deoxygenated states. In contrast, the lower panel depicts sickle hemoglobin (HbSS), where the Glu6Val substitution promotes intermolecular interactions leading to fiber formation and red cell deformation. This structural comparison visually demonstrates how a single amino acid substitution in the β-globin chain results in profound changes to hemoglobin function and red blood cell morphology. In heterozygotes (HbAS), approximately 60% of total hemoglobin is HbA and 40% HbS, resulting in largely normal erythrocyte physiology under normoxic conditions. However, under low oxygen tension, mild polymerization can occur, leading to transient cell sickling and reversible structural perturbations. These temporary conformational changes are fundamental to the molecular basis of malaria protection, as they influence parasite development, nutrient transport, and cytoadherence within erythrocytes.



Figure 2 Structure and genetics of normal hemoglobin (HbA) and sickle hemoglobin (HbS). The upper panel represents normal HbAA, while the lower panel illustrates the structural deformation of HbSS caused by the Glu6Val mutation.[15]

Mechanism of inheritance and global distribution of HBS allele

The HbS allele follows a Mendelian autosomal recessive inheritance pattern, as illustrated in Figure 3. Homozygous individuals (HbSS) express the full clinical manifestations of sickle cell disease,

Citation: Abah MA, Archibong EU, Oladosu MA, et al. The protective role of sickle cell trait against plasmodium falciparum malaria. *J Hum Virol Retrovirol.* 2025;12(1):23–31. DOI: 10.15406/jhvrv.2025.12.00283

characterized by chronic hemolytic anemia, vaso-occlusive crises, and multi-organ complications. In contrast, heterozygous carriers (HbAS) are typically asymptomatic but exhibit significant resistance to *Plasmodium falciparum* malaria due to reduced parasite survival within their red blood cells. This heterozygote advantage exemplifies balanced polymorphism, wherein a deleterious allele persists in the gene pool because it confers a selective benefit under specific environmental pressures. The persistence of the HbS allele in malaria-endemic regions highlights the intricate interplay between genetic variation and natural selection in shaping human populations.[8,17]

Figure 3 Inheritance of sickle cell disease. In a scenario where both parents



have a sickle cell trait (SCT, HbAS), each pregnancy carries a 25% chance of normal offspring (HbAA), a 50% chance of offspring with SCT, and a 25% chance of offspring with sickle cell disease (HbSS).[16]

As illustrated in Figure 4, the global distribution of the HbS allele varies considerably across geographic regions. The map depicts allele frequencies across the American, European, Southeast Asian, African, Western Pacific, and Eastern Mediterranean regions, with the African region showing the highest prevalence. This distribution closely parallels historical malaria endemicity, underscoring the selective advantage conferred by heterozygosity in regions where malaria transmission is or was intense. Population genetic analyses indicate that the HbS mutation arose independently in at least five ancestral populations corresponding to the Benin, Bantu, Cameroon, Senegal, and Arabian-Indian haplotypes reflecting convergent evolution under strong malarial selection.[19,20] Molecular population studies using haplotype mapping and genome-wide association analyses further reveal that the selection coefficient for HbS in malaria-endemic areas ranges between 0.05 and 0.2, among the strongest reported for any human gene.[21] The persistence of this allele, despite the deleterious effects of homozygosity, demonstrates the extraordinary influence of infectious disease in shaping human genomic diversity and regional adaptation.



Figure 4 Global distribution of HbS allele. The map illustrates the global distribution of the HbS allele across major world regions, including the Americas, Europe, Southeast Asia, Africa, the Western Pacific, and the Eastern Mediterranean. The African region exhibits the highest HbS allele frequency, corresponding with areas of intense historical malaria transmission.[18]

Concept of balanced polymorphism and heterozygote advantage

Balanced polymorphism refers to the maintenance of multiple alleles in a population due to selective forces favouring heterozygous genotypes. The sickle cell trait remains the most prominent example of this evolutionary phenomenon in humans.[8,22] The HbAS genotype offers a "heterozygote advantage," wherein carriers experience substantial protection against severe *P. falciparum* malaria while avoiding the pathological manifestations of sickle cell disease (HbSS). The theoretical framework for this selection dynamic is often modeled using the concept of overdominance, where heterozygotes exhibit higher relative fitness compared to both homozygotes.[7] (Figure 5).



Figure 5 Balanced polymorphism and heterozygous advantage. The disadvantage of sickle cell homozygotes (HbSS), who often die early due to vaso-occlusive complications, is balanced by the advantage of heterozygotes (HbAS). Individuals with normal haemoglobin (HbAA) are more susceptible to severe malaria, particularly in early childhood. The presence of HbS in heterozygotes inhibits malaria parasite replication without causing major sickle cell symptoms, providing protection against both diseases. This selective advantage promotes the persistence of the HbS allele in malaria-endemic regions.[23]

Mathematical modeling and empirical data have shown that the equilibrium frequency of HbS correlates strongly with malaria transmission intensity.[21] Thus, as malaria burden declines through public health interventions, the evolutionary advantage of HbAS may wane, leading to potential shifts in allele prevalence in future generations.

Evolutionary selection pressure exerted by malaria on the β-globin gene

Malaria has acted as a powerful selective agent throughout human evolutionary history. The emergence of *P. falciparum* approximately 10,000 years ago coincided with the spread of agriculture and the expansion of mosquito habitats, intensifying transmission and selection pressures on human hosts.[24] The HbS allele's strong association with historical malaria prevalence supports its adaptive origin as a protective mutation.[19] Functional studies demonstrate that HbAS erythrocytes restrict parasite growth and reduce cytoadherence, effectively diminishing severe disease risk.

Citation: Abah MA, Archibong EU, Oladosu MA, et al. The protective role of sickle cell trait against plasmodium falciparum malaria. *J Hum Virol Retrovirol.* 2025;12(1):23–31. DOI: 10.15406/jhvrv.2025.12.00283

Evolutionary genomic analyses reveal that the β-globin locus exhibits one of the highest values among human populations, confirming intense local adaptation.[19] The persistence of HbAS in malaria-endemic regions exemplifies an evolutionary trade-off between protective advantage and genetic cost, an enduring hallmark of host–pathogen coevolution. Understanding this dynamic provides not only insight into human adaptation but also potential translational value for designing host-based antimalarial interventions.

Epidemiological evidence of protection

Epidemiological data form the cornerstone of our understanding of the protective effect conferred by the sickle cell trait (HbAS) against *Plasmodium falciparum* malaria. Since the pioneering work of Allis,[8] extensive field and clinical studies have consistently shown that individuals with HbAS exhibit significantly lower susceptibility to severe malaria outcomes compared to those with normal hemoglobin (HbAA). While infection rates may remain similar between groups, HbAS confers remarkable protection against severe manifestations such as cerebral malaria and severe anemia.[7,11]

Foundational epidemiological studies and replication across populations

Allison's early work in East Africa demonstrated a strong inverse relationship between HbAS frequency and malaria incidence.[8] Subsequent studies across Africa and other endemic regions have confirmed this relationship, cementing HbAS as a genetic determinant of malaria resistance.[17] (Table 1). In that study, the incidence of hospitalization for malaria was markedly lower among HbAS children than among those with normal hemoglobin (HbAA), indicating approximately 75% protection against severe malaria, while hospitalization rates for non-malarial illnesses remained comparable between genotypes. More recent analyses, including multi-country genome-wide association studies, have reinforced this association, showing that HbAS carriers experience up to an 80% reduction in the risk of severe P. falciparum malaria.[25] In large-scale population studies conducted in Kenya and The Gambia, HbAS individuals were found to have markedly reduced rates of hospital admission and mortality related to severe malaria.[11] Importantly, this protective effect was strongest in children aged 2–10 years, the demographic most vulnerable to severe malaria before acquiring natural immunity (Table 1).[10]

Table 1 Incidence of hospitalization for malaria and other diseases, by hemoglobin genotypes

Diagnosis,[8] hemoglobin genotype	No. of episodes	Incidence (no. of episodes/1000 cyfu)	IRR (95% CI)	P
Nonmalaria				
All nonmalaria				
AA	512	57.83	1	
AS	72	47.72	0.84 (0.60-1.17)	0.289
Lower respiratory tract infection				
AA	271	30.55	1	
AS	43	28.5	0.96 (0.63-1.46)	0.857
Gastroenteritis				
AA	83	9.36	1	
AS	8	5.3	0.59(0.28-1.21)	0.15
Malnutrition				
AA	11	1.24	1	
AS	2	1.33	1.14(0.17-7.56)	0.895
Accidents				
AA	24	2.7	1	
AS	4	2.65	0.94(0.31-2.88)	0.916
Severe anemia without malarial parasites				
AA	18	2.01	1	
AS	1	0.66	0.35(0.05-2.59)	0.302
Malaria				
All malaria				
AA	536	60.42	1	
AS	25	16.57	0.25(0.16-0.39)	<.0001
All severe malaria				
AA	191	21.53	1	
AS	6	3.98	0.17(0.07-0.40)	<.0001
Cerebral malaria[b]				
AA	34	3.83	1	
AS	1	0.66	0.14(0.02-1.17)	0.07
Severe malarial anemia with >10,000 parasites/4[c]				
AA	48	5.41	1	
AS	1	0.66	0.11(0.01-0.97)	0.047

Citation: Abah MA, Archibong EU, Oladosu MA, et al. The protective role of sickle cell trait against plasmodium falciparum malaria. *J Hum Virol Retrovirol.* 2025;12(1):23–31. DOI: 10.15406/jhvrv.2025.12.00283

Table 1 Continued.....

Malaria with convulsions (2 or more seizures during the previous 24 h)[b]				
AA	94	10.6	1	
AS	4	2.65	0.23(0.08-0.67)	0.007

Epidemiological models consistently estimate that HbAS reduces the risk of severe malaria by approximately 70–90%, while offering 30–50% protection against uncomplicated malaria.[13] For instance, a meta-analysis by Taylor et al. Reported that HbAS carriers had a 2- to 10-fold lower risk of severe malaria syndromes. According to *Williams* et al.,[10] children carrying the sickle cell trait (HbAS) experience substantial protection against *Plasmodium falciparum* malaria. Their findings indicate that HbAS confers about 50% protection against mild clinical malaria and up to 90% protection against severe or hospital-admitted cases, while showing little effect on asymptomatic infections (Figure 6). Williams and colleagues therefore emphasized that the selective advantage of HbAS lies primarily in its strong protection against life-threatening malaria rather than in the prevention of infection. In high-transmission regions of sub-Saharan Africa, the protective advantage of HbAS corresponds with enhanced childhood survival rates, contributing to the maintenance of the HbS allele through natural selection.[21]



Figure 6 Geometric mean parasite density. Children with sickle cell trait (HbAS) had markedly lower *Plasmodium falciparum* parasite densities and fewer malaria episodes than those with normal hemoglobin (HbAA). HbAS children showed reduced parasite loads in symptomless parasitemia and mild clinical malaria (P = .009), and significantly fewer hospital admissions for malaria (P < .0001), indicating strong protection of the sickle cell trait against malaria infection and severity.[10]

Variation in protective efficacy by region, age, and malaria transmission intensity

The strength of HbAS-mediated protection against *Plasmodium falciparum* infection varies geographically with transmission intensity, environmental conditions, and host factors. The greatest protective advantage is observed in regions of high perennial transmission, such as West and Central Africa, where HbS allele frequencies reach 10–20%.[26] In contrast, in areas of low or unstable transmission—such as East Africa and parts of India—the protective effect is reduced, reflecting weaker selective pressure. Age-related variation also influences this protection; the benefit of HbAS declines with age as individuals acquire naturally acquired immunity[11] These geographic and demographic patterns are consistent with parasitemia prevalence trends shown in Figure 7, where P. falciparum infection rates vary across age categories and study sites.[27]



Figure 7 *Plasmodium falciparum* parasitemia prevalence measured by microscopy, by age category, and by site. 6 M to < 5 Y = 6 months to younger than 5 years; 5 Y to < 10 Y = 5 years to younger than 10 years. Error bars depict 95% CI.[27]

Limitations and confounding factors in epidemiological interpretations

Despite strong evidence, several confounding factors complicate interpretation. Coinheritance of other red cell polymorphisms such as α-thalassemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency may alter the degree of protection, sometimes in antagonistic ways. Environmental variables, socioeconomic status, and healthcare access further influence epidemiological outcomes.[6] Diagnostic heterogeneity, particularly in distinguishing severe malaria from other febrile illnesses, remains a key methodological challenge. Nonetheless, convergent epidemiological findings across regions affirm HbAS as the most potent naturally selected genetic defense against *P. falciparum* malaria.

Mechanisms of malaria protection in sickle cell trait (HbAS)

Sickle cell trait (HbAS) confers protection against *Plasmodium falciparum* through a coordinated interplay of erythrocyte-intrinsic alterations, innate immune modulation, and adaptive immune enhancement. These complementary mechanisms disrupt parasite growth, facilitate early clearance of infected erythrocytes, and regulate host inflammatory responses, collectively reducing the risk of severe malaria.

HbAS erythrocytes display unique biochemical and biophysical properties that interfere with multiple stages of parasite development. While parasite invasion rates remain comparable to HbAA erythrocytes, maturation and replication are markedly impaired under physiological hypoxia due to HbS polymerization. This increases cytoplasmic viscosity and alters nutrient exchange, resulting in delayed parasite development and lower parasitemia.[7,21] Infected HbAS erythrocytes selectively undergo reversible sickling under low oxygen tension, compromising schizogony and promoting splenic clearance of late-stage parasites.[28] Chronic oxidative stress within HbAS cells, driven by unstable HbS and intermittent polymerization, generates reactive oxygen species (ROS) and haemichromes that

disrupt parasite transcription, protein synthesis, and hemoglobin catabolism.[20,29]

Concurrently, alterations in erythrocyte membrane structure, including impaired PfEMP1 trafficking and knob formation, reduce cytoadherence and enhance recognition by phagocytes.[7,30] Together, these erythrocyte-intrinsic effects form a first line of defense, restricting parasite growth and promoting clearance (Figure 8, steps 1–7).

Beyond these intrinsic effects, HbAS profoundly modulates innate immune responses. Phosphatidylserine exposure and other surface alterations on stressed erythrocytes enhance recognition and phagocytosis by macrophages, neutrophils, and dendritic cells through scavenger receptor–mediated pathways.[11] Heme released from unstable HbS induces heme oxygenase-1 (HO-1), which exerts cytoprotective and anti-inflammatory effects while modulating monocyte and dendritic cell activation.[32] Hemolysis-associated induction of inducible nitric oxide synthase (iNOS) elevates nitric oxide bioavailability, restricting intraerythrocytic parasite growth through nitrosative stress and preventing excessive proinflammatory cytokine release.[33] Neutrophils demonstrate enhanced oxidative burst capacity, and natural killer (NK) cells exhibit heightened cytotoxicity, collectively contributing to early containment of blood-stage parasites.[34] These innate immune mechanisms synergize with erythrocyte-level stress, amplifying parasite clearance while limiting tissue damage (Figure 8, steps 6–8).



Figure 8 Multiple mechanisms of resistance in sickle cell trait (HbAS). Elevated oxidative stress and host microRNAs in HbAS erythrocytes disrupt parasite growth (1), suppressing transcription and protein synthesis (2). Impaired actin structure hinders Maurer's cleft formation and protein trafficking (3), while haemichromes block surface expression of PfEMP (4). Reduced PfEMP weakens cytoadherence, promoting splenic clearance of infected cells (5). Oxidative stress further increases haemichrome formation (6), inducing band 3–mediated senescence and phagocytosis (7). Enhanced phagocytic activity stimulates immune responses (8), and antibody production against parasite proteins reinforces this clearance (9).[31]

HbAS also accelerates adaptive immune responses. Repeated low-level parasitemia in carriers enhances T- and B-cell priming, fostering efficient immunological memory against parasite antigens.[35] Antibody-mediated recognition further reinforces phagocytic clearance of infected erythrocytes (Figure 8, step 9), complementing both erythrocyte-intrinsic and innate immune mechanisms.

In summary, HbAS confers malaria protection through a multi-layered system in which intracellular erythrocyte stress, innate immune amplification, and adaptive immune memory act in concert. Oxidative and nitrosative stress disrupt parasite growth and protein trafficking, selective sickling enhances splenic clearance, and immune modulation ensures effective pathogen recognition while controlling inflammatory damage. This integrated mechanism efficiently limits parasitemia, reduces severe disease risk, and accelerates the acquisition of immunity, as depicted in Figure 8.

Evolutionary medicine and population health perspectives

The sickle cell trait (HbAS) exemplifies one of the most striking cases of gene–environment coevolution in human history, representing a powerful demonstration of how infectious disease can shape the genetic landscape of populations. The persistence of the HbS allele in malaria-endemic regions is an outcome of balanced polymorphism, where heterozygous individuals (HbAS) gain a survival advantage against *Plasmodium falciparum* malaria, while homozygotes (HbSS) suffer the severe morbidity and mortality of sickle cell disease.[21] This evolutionary trade-off highlights the duality of genetic adaptation where the same mutation can be both protective and pathogenic depending on zygosity and environmental context.

From an evolutionary medicine perspective, the HbS allele's distribution aligns closely with historical malaria transmission zones across sub-Saharan Africa, the Middle East, and parts of South Asia (Figure 4). The spatial overlap between HbS prevalence and P. falciparum endemicity supports the hypothesis that malaria exerted strong selective pressure on human populations over the past 5,000–7,000 years.[22] This selective advantage is estimated to confer a 60–90% reduction in severe malaria mortality among heterozygotes, sufficient to maintain the allele at relatively high frequencies despite the fitness cost in homozygotes.[7] The equilibrium between malaria pressure and genetic disease burden forms a classical example of natural selection acting on human health.

At the population level, the relationship between HbAS and malaria continues to evolve in response to ecological and epidemiological transitions. Declines in malaria transmission due to vector control, socioeconomic development, and chemotherapeutic interventions may gradually alter the selective landscape, potentially reducing the frequency of the HbS allele in future generations.[17] However, this dynamic is complex—local variations in transmission intensity, population migration, and admixture patterns influence allele persistence.[26] In regions undergoing malaria elimination, such as parts of East Africa and Southeast Asia, the long-term evolutionary trajectory of HbS remains an open question, as selective pressure wanes but genetic drift and demographic factors persist.

From a public health standpoint, the coexistence of HbAS advantage and HbSS pathology poses significant challenges. In endemic regions, sickle cell disease continues to account for substantial childhood morbidity and mortality, particularly where neonatal screening and disease management are limited. The same evolutionary forces that favored HbAS survival have thus indirectly perpetuated a major hematological disorder. Integrating evolutionary insights into health systems can inform strategies for genetic counseling, premarital screening, and population-level interventions that balance the benefits of malaria protection with the burdens of sickle cell disease. Such evolutionary awareness is vital for shaping ethical and culturally sensitive policies in sub-Saharan Africa and other endemic regions.[21]

Ultimately, the evolutionary dialogue between P.falciparum and the human genome underscores the interconnectedness of genetics, environment, and disease ecology. The HbAS trait represents not merely a defensive mutation but a paradigm of evolutionary compromise, one that illustrates how selective pressures can both protect and harm human populations. As malaria control progresses and global health landscapes shift, monitoring the evolutionary dynamics of HbS will remain essential for anticipating changes in genetic disease prevalence and guiding precision public health strategies.[7,10]

The lessons drawn from this gene–parasite coevolution extend beyond malaria, offering a framework for understanding how evolutionary forces continue to shape human susceptibility and resilience to infectious diseases in the modern era.

Future directions and research priorities

Despite substantial progress in elucidating the protective mechanisms of the sickle cell trait (HbAS) against *Plasmodium falciparum* malaria, several critical gaps remain in our mechanistic and translational understanding. Future research must integrate multidisciplinary approaches to dissect the complex interplay between genetic, cellular, and immunological factors that confer protection. Although the epidemiological correlation between HbAS and malaria resistance is well established, the precise molecular pathways that mediate reduced parasite growth and attenuated disease severity remain only partially defined.[7]

Advancements in omics technologies including genomics, transcriptomics, proteomics, and metabolomics offer promising tools for unraveling the intricate molecular responses induced by HbAS erythrocytes during malaria infection. Multi-omics integration can identify key regulatory nodes linking hemoglobin polymerization dynamics, redox homeostasis, and immune modulation.[21] In particular, immunometabolic profiling may clarify how altered erythrocyte metabolism in HbAS individuals shapes innate and adaptive immune responses, providing potential biomarkers for protective immunity and disease tolerance.[10]

The role of epigenetic regulation represents another frontier of investigation. Epigenetic modifications affecting erythropoiesis, oxidative stress responses, and inflammatory gene expression may fine-tune host–parasite interactions in HbAS carriers. Understanding these mechanisms could reveal reversible pathways that mimic the HbAS phenotype, enabling the design of host-targeted therapeutics that replicate its protective effects without genetic modification. Moreover, integrating CRISPR-based functional genomics and single-cell technologies can advance our comprehension of genotype-specific parasite–host interactions at unprecedented resolution.

Translationally, insights from HbAS-mediated protection hold promise for vaccine development and therapeutic innovation. Identifying molecular determinants of reduced parasite invasion and enhanced immune clearance could inform the design of vaccines that leverage host genetic advantages.[26] Additionally, precision medicine approaches that account for hemoglobin genotype may optimize antimalarial drug efficacy and vaccine responsiveness across populations. Finally, long-term population-based cohort studies should monitor how declining malaria transmission and demographic transitions influence HbS allele frequency and selection dynamics, guiding both evolutionary modeling and genetic counseling in endemic regions.[34]

Conclusion

The sickle cell trait (HbAS) remains one of the most profound examples of natural selection driven by infectious disease. Its protective role against *Plasmodium falciparum* malaria illustrates how a single genetic variant can profoundly influence human survival and population genetics in endemic regions. Through balanced polymorphism, the HbS allele persists where malaria is prevalent, offering heterozygotes substantial survival advantage while imposing severe costs in homozygous individuals.[22] Protection in HbAS arises from multifactorial mechanisms that span molecular, cellular, and immunological levels. Altered erythrocyte physiology, increased oxidative stress, and restricted parasite growth create an intracellular environment unfavourable to P. falciparum development. Concurrently, modulation of immune responses—particularly macrophage activity and cytokine balance—enhances parasite clearance and disease tolerance without conferring sterilizing immunity.[10]

From an evolutionary and clinical standpoint, the HbAS–malaria interaction underscores the dynamic interplay between genetics, environment, and disease ecology. It exemplifies how adaptive mutations may yield both evolutionary benefits and pathological consequences within human populations.[26]

As malaria control intensifies and transmission declines, the selective advantage of HbAS may gradually diminish, yet its biomedical relevance endures. Future translational research should leverage insights from HbAS-mediated protection to inform host-targeted therapies, vaccine development, and genetic counseling strategies. Understanding this genotype's resilience mechanisms may inspire innovative interventions that replicate natural defense pathways against malaria and other infectious diseases. Ultimately, the sickle cell trait represents not only a milestone in human evolutionary medicine but also a blueprint for harnessing genetic adaptation to advance global health. A comprehensive summary of the key findings from this study, encompassing the mechanisms, evidence and evolutionary implications discussed throughout, is presented in Table 2.

Table 2 Summary of Key Findings

Domain	Summary of key findings
Mechanistic Basis of Protection	The sickle cell trait (HbAS) confers protection against P. falciparum malaria through an interplay of genetic, cellular, and immunological mechanisms. The β-globin mutation (Glu6Val) leads to mild polymerization of HbS under hypoxia, inducing transient erythrocyte sickling that restricts parasite invasion and replication. Altered redox homeostasis and increased oxidative stress impair parasite metabolism and promote early clearance of infected cells by the spleen. Additionally, HbAS enhances macrophage phagocytosis, modulates cytokine responses, and increases nitric oxide bioavailability, collectively promoting disease tolerance and limiting severe inflammatory pathology. These multifaceted effects reduce parasite density and prevent progression to severe malaria syndromes without eliminating infection entirely.[10,21]

Table 2 Continued.....

Epidemiological and Clinical Evidence	Population studies consistently demonstrate a 60–90% reduction in severe malaria and mortality among HbAS individuals, especially in early childhood. HbAS carriers show lower parasite burdens, reduced rates of cerebral malaria and severe anemia, and improved survival in endemic regions. These effects vary with transmission intensity and age but remain significant across diverse populations, confirming a robust epidemiological advantage.[10,22,26]
Evolutionary and Population Health Implications	The persistence of the HbS allele exemplifies balanced polymorphism, maintained by selective pressure from malaria despite the health burden of homozygous HbSS disease. This gene–environment equilibrium underscores the evolutionary trade-off between survival advantage and genetic cost. As malaria control improves, selective pressure may decline, potentially altering HbS frequency. Understanding this dynamic is crucial for genetic counseling, public health policy, and malaria elimination strategies.[21,35]
Translational and Future Perspectives	Decoding HbAS-mediated protection offers opportunities for biomedical innovation. Insights into HbAS-linked oxidative stress responses, erythrocyte signaling, and immune regulation can inform host-directed antimalarial therapies and vaccine design. Integrating genomic and epigenetic studies may reveal targets that mimic natural protective mechanisms without genetic alteration.[7,10]

Acknowledgement

We thank all the researchers who contributed to the success of this research work.

Conflict of interest

The authors declared that there are no conflicts of interest.

Funding

No funding was received for this research work.

References

1. Poostchi M, Silamut K, Maude RJ, et al. Image analysis and machine learning for detecting malaria. Translational Research. *Transl Res*. 2018;194:36–55.
2. World Health Organization. World malaria report. Tracking progress and gaps in the global response to malaria, Geneva. *WHO*. 2023.
3. Cowman AF, Healer J, Marapana D, et al. Malaria: Biology and Disease. *Cell*. 2016;167(3):610–624.
4. Clark M, Goheen MM, Cerami C. Influence of host iron status on *Plasmodium falciparum* infection. *Front Pharmacol*. 2014;5:84.
5. Miller LH, Ackerman HC, Su XZ, et al. Malaria biology and disease pathogenesis: insights for new treatments. *Nat Med* 2013;19(2):156–167.
6. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. American journal of human genetics. *Am J Hum Genet*. 2005;77(2):171–192.
7. Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies: Slicing the gordian knot of *plasmodium falciparum* malaria pathogenesis. *PLoS Pathog* 2013;9(5):e1003327.
8. Allison AC. Protection afforded by sickle–cell trait against subtertian malareal infection. *Br Med J*.1954;1(4857):290–294.
9. Rahmawati N, Triani E. Sickle Cell Trait and Protection against Malaria: Review Literature. *Green Medical Journal*.2025.
10. Williams TN, Mwangi TW, Wambua S, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. *J Infect Dis*. 2005;192(1):178–186.
11. Ndila CM, Uyoga S, Macharia AW, et al. Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case–control association study. The Lancet. *Lancet Haematol*. 2018;5(8):e333–e345.
12. Luzzatto L. Sickle cell anaemia and malaria. Mediterranean journal of hematology and infectious diseases. *Mediterr J Hematol Infect Dis.* 2012;4(1):e2012065.
13. Orkin SH and Bauer DE. Emerging genetic therapy for sickle cell disease. *Annu Rev Med*. 2019;70:257–271.
14. Marengo–Rowe AJ. Structure–function relations of human hemoglobins. Proceedings (Baylor University. Medical Center). *Proc (Bayl Univ Med Cent)*. 2006;19(3):239–245.
15. Ramadas N, Sparkenbaugh EM. The APC–EPCR–PAR1 axis in sickle cell disease. Frontiers in Medicine. *Front Med (Lausanne)*. 2023;11(10):1141020.
16. Egesa WI, Nakalema G, Waibi WM, et al. Sickle cell disease in children and adolescents: a review of the historical, clinical, and public health perspective of sub–saharan africa and beyond. *Int J Pediatr*. 2022;12:1–26.
17. Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. *Cold Spring Harb Perspect Med*. 2012;2(9):a011692.
18. Al–Judaibi B, Alzahrani H, Al–Ahmari A, et al. Emerging need for a hepato–hematology program for patients with sickle cell disease in Saudi Arabia. *Saudi J Gastroenterol*. 2025;31(2):53–58.
19. Shriner D, Rotimi CN. Whole–Genome–Sequence–Based Haplotypes Reveal Single Origin of the Sickle Allele during the Holocene Wet Phase. *Am J Hum Genet*. 2018;102(4):547–556.
20. Luzzatto L, Arese P. Favism and Glucose–6–Phosphate Dehydrogenase Deficiency. *N Engl J Med*. 2018;378(1):60–71.
21. Kariuki SN, Williams TN. Human genetics and malaria resistance. *Hum Genet*. 2020;139(6–7):801–811.
22. Hedrick PW. Population genetics of malaria resistance in humans. *Heredity*. 2011;107(4)l283–304.
23. Piccin A, Murphy C, Eakins E, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. European Journal of Haematology. *Eur J Haematol*. 2019;102(4):319–330.
24. Carter, R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. *Clin Microbiol Rev*. 2002;15(4):564–594.
25. Malaria Genomic Epidemiology Network. Insights into malaria susceptibility using genome–wide data on 17,000 individuals from Africa, Asia and Oceania. *Nat Commun*. 2019;10(1):5732.
26. Piel FB, Howes RE, Patil AP, et al. The distribution of haemoglobin C and its prevalence in newborns in Africa. *Sci Rep*. 2013;3:1671.
27. Adeniji E, Asante KP, Boahen O. Estimating Annual Fluctuations in Malaria Transmission Intensity and in the Use of Malaria Control Interventions in Five Sub–Saharan African Countries. *Am J Trop Med Hyg*. 2020;103(5):1883–1892.
28. Moxon CA, Grau GE, Craig AG. Malaria: modification of the red blood cell and consequences in the human host. *Br J Haematol*. 2011;154(6):670–679.
29. Vasquez M, Zuniga M. Rodriguez A. Oxidative stress and pathogenesis in malaria. Frontiers in cellular and infection microbiology. *Front Cell Infect Microbiol*. 2021;11:768182.

30. Cyrklaff M, Sanchez CP, Kilian N, et al. Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum–infected erythrocytes. *Science*. 2011;334(6060):1283–6

31. Lelliott P, Mcmorran BJ, J Foote, S, et al. The influence of host genetics on erythrocytes and malaria infection: Is there therapeutic potential. *Malar J.* 2015;29(14):289.

32. Epiphanio S, Mikolajczak SA, Gonçalves LA, et al. Heme oxygenase–1 is an anti–inflammatory host factor that promotes murine plasmodium liver infection. *Cell Host Microbe*. 2008;3(5):331–338.

33. Nahrevanian H. Immune effector mechanisms of the nitric oxide pathway in malaria: cytotoxicity versus cytoprotection. *Braz J Infect Dis*.2006;10(4):283–92.

34. Aitken EH, Alemu, A, Rogerson SJ. Neutrophils and malaria. *Front Immunol*. 2018;19(9):3005.

35. Williams, T. N. Human red blood cell polymorphisms and malaria. *Curr Opin Microbiol*.2006;9(4):388–94.

36. Yalla AR. Sickle cell trait and resistance to malaria: a review. *Pod Literature Review*. 2025.

Citation: Abah MA, Archibong EU, Oladosu MA, et al. The protective role of sickle cell trait against plasmodium falciparum malaria. *J Hum Virol Retrovirol.* 2025;12(1):23–31. DOI: 10.15406/jhvrv.2025.12.00283